Intracranial Hemorrhage Risk with NOACs vs Aspirin

MedicalResearch.com Interview with:
medical researchDr. Michael Lee
Department of Neurology
Chang Gung University College of Medicine
Chang Gung Memorial Hospital Taiwan

MedicalResearch.com: What is the background for this study?

Response: Although NOACs and aspirin are in general protective in different vascular beds, NOACs might be an attractive choice for stroke prevention in certain clinical situations, such as in people without recognized atrial fibrillation, but with an embolic stroke of undetermined source or atrial cardiopathy because of their propensity to also cause stroke through cardiac emboli.

Nonetheless, the benefit of NOACs over aspirin for stroke protection is likely to be less promising in people without atrial fibrillation, as compared to people with atrial fibrillation. Therefore it is even more important to clarify whether individual NOACs with of various doses harbor comparable risks of intracranial hemorrhage with aspirin based on the evidence currently available.

MedicalResearch.com: What are the main findings? 

Response: Rivaroxaban 15-20mg once daily substantially increased the risks of intracranial hemorrhage while rivaroxaban 10mg daily and apixaban 5mg twice daily were not. 

MedicalResearch.com: What should readers take away from your report?

Response: Rivaroxaban 15-20mg once daily possessed substantial higher risks of intracranial hemorrhage than aspirin, its use in people without atrial fibrillation could not be encouraged.  

MedicalResearch.com: What recommendations do you have for future research as a result of this work? 

Response: It may be worthwhile to conduct randomized controlled trials comparing certain NOAC (e.g. apixaban 5mg twice daily) and aspirin in patients without atrial fibrillation, but with potential sources of cardiac emboli that can cause stroke.

No disclosures 

Citation:

Huang W, Singer DE, Wu Y, et al. Association of Intracranial Hemorrhage Risk With Non–Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin UseA Systematic Review and Meta-AnalysisJAMA Neurol. Published online August 13, 2018. doi:10.1001/jamaneurol.2018.2215

 

Aug 15, 2018 @ 12:30 pm

 

 

 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.